Roberto Constantino Tapia Conyer

Patia Europe SL is a public health company based in Donostia-San Sebastián, Spain. The Spanish company integrates genetic, metabolomic, and digital tools to facilitate the prevention and control of type 2 diabetes. Patia's team has extensive experience in the fields of molecular biology and genomic medicine, complemented by top-level alliances with prestigious research centers in and the Americas to make the most advanced genomic and technological tools available to the population in the most accessible way. Patia offers a laboratory test called Diabetespredict™, which provides an evaluation of high sensitivity and specificity of the genetic predisposition to develop type 2 diabetes (DT2). Additionally, it offers personalized recommendations based on the patient's genetics. The test has been developed in collaboration with scientists and endocrinologists from the Hospital General de. Patia also works to reduce the effects of the COVID-19 pandemic on people with diabetes.